Abstract
Non-specific immunopotentiators, such as polysaccharide K (PSK), also known as OK-432, induce anti-tumor effects via immunological responses. The efficacy of combination immunochemotherapy using these immunopotentiators has been examined by multiple previous studies. The survival benefits of immunochemotherapy for patients with curative resections of gastric cancers are not widely accepted. To clarify this issue, we performed a meta-analysis to evaluate the effect of immunochemotherapy on survival in patients with curative resections of gastric cancer. For this study, we compared the results of chemotherapy and immunotherapy using the biological response modifier PSK as an immunopotentiator. The meta-analysis included 8,009 patients from eight randomized controlled trials after central randomization. The overall hazard ratio for eligible patients was 0.88 (95% confidence interval, 0.79–0.98; P = 0.018) with no significant heterogeneity [χ 2(8) for heterogeneity = 11.7; P = 0.16]. The results of this meta-analysis suggest that adjuvant immunochemotherapy with PSK improves the survival of patients after curative gastric cancer resection.
Similar content being viewed by others
References
Ferlay J, Bray F, Pisani P et al (2004) GLOBOCAN 2002. Cancer incidence, mortality and prevalence worldwide. IARC CancerBase No. 5, version 2.0. IARC, Lyon
Sastre J, García-Saenz JA, Díaz-Rubio E (2006) Chemotherapy for gastric cancer. World J Gastroenterol 12:204–213
Kobayashi H, Matsunaga K, Oguchi Y (1995) Antimetastatic effects of PSK (Krestin), a protein-bound polysaccharide obtained from basidiomycetes: an overview. Cancer Epidemiol Biomarkers Prev 4:275–281
Ohno R, Yamada K, Masaoka T et al (1984) A randomized trial of chemoimmunotherapy of acute nonlymphocytic leukemia in adults using a protein-bound polysaccharide preparation. Cancer Immunol Immunother 18:149–154
Sakamoto J, Morita S, Oba K et al (2006) Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curatively resected colorectal cancer: a meta-analysis of centrally randomized controlled clinical trials. Cancer Immunol Immunother 55:404–411
Nakazato H, Koike A, Saji S, Ogawa N, Sakamoto J (1994) Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer. Lancet 343:1122–1126
Nakajima T, Inokuchi K, Hattori T et al (1989) Multi-institutional cooperative study of adjuvant immunochemotherapy in gastric cancer—five-year survival rate (in Japanese). Gan To Kagaku Ryoho 16:799–806
Kim R, Yoshida K, Toge T (2002) Current status and future perspectives of post-operative adjuvant therapy for gastric carcinoma. Anticancer Res 22:283–289
Ikuzawa M, Matsunaga K, Nishiyama S et al (1988) Fate and distribution of an antitumor protein-bound polysaccharide PSK (Krestin). Int J Immunopharmacol 10:415–423
Higgins JPT, Green S (eds) (2005) Assessment study quality. Cochrane handbook for systematic reviews of interventions 4.2.5 [updated May 2005]; Section 6. The Cochrane Library, Issue 3. Wiley, Chichester, UK
Parmar MB, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17:2815–2834
DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188
Niimoto M, Hattori T, Tamada R, Sugimachi K, Inokuchi K, Ogawa N (1988) Postoperative adjuvant immunochemotherapy with mitomycin C, futraful and PSK for gastric cancer. An analysis of data on 579 patients followed for five years. Jpn J Surg 18:681–686
Kondo T, Ichihashi H, Nakazato H, Ogawa N (1989) Result of adjuvant immunochemotherapy on 8 year survival using Krestin and Futraful for gastric cancer patients who underwent radical gastrectomy—a randomized controlled trial by cooperative study group (in Japanese). Biotherapy 3:655–664
Kondo T, Sakamoto J, Nakazato H (1991) Alternating immunochemotherapy of advanced gastric carcinoma: a randomized comparison of carbazilquinone and PSK to carbazilquinone in patients with curative gastric resection. Biotherapy 3:287–295
Ogawa M, Kako H, Kitano T et al (1994) Cooperative study of adjuvant immunochemotherapy using HUFU (Mifurol®) for gastric cancer patients who underwent curative resection (in Japanese). Rinsyo To Kenkyu 71:201–206
Nakazato H, Koike A, Saji S, Ogawa N, Sakamoto J (1994) Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer. Lancet 343:1122–1126
Ochiai T, Sato H, Sato H et al (1983) Randomly controlled study of chemotherapy versus chemoimmunotherapy in postoperative gastric cancer patients. Cancer Res 43:3001–3007
Fujimoto S, Furue H, Kimura T et al (1984) Clinical evaluation of schizophyllan adjuvant immunochemotherapy for patients with resectable gastric cancer—a randomized controlled trial. Jpn J Surg 14:286–292
Kanabe S, Tamakuma S, Mimura K et al (1985) Comparison of immunochemotherapy and chemotherapy of stage IV gastric carcinoma (in Japanese). Gan No Rinsho 31:1805–1809
Sato S (1989) Study of validation of post-operative adjuvant chemotherapy following curative resection of stage II, III gastric cancer (in Japanese). Tokyo Ika Daigaku Zasshi 47:297–308
Nio Y, Tobe T (1989) Immunity of gut-associated lymphoid tissue and the role of the oral immunotherapy in multi-disciplinary treatment of the digestive organ cancer (in Japanese). Nippon Geka Gakkai Zasshi 90:1436–1438
Imaizumi M, Kondo T, Kamei H, Ichihashi H (1990) Cooperative study on surgical adjuvant immunochemotherapy for prevention of postoperative recurrence of gastric cancer (II). Cooperative study group on surgical adjuvant immunochemotherapy for prevention of postoperative recurrence of gastric cancer supported by the Ministry of Health and Welfare (Kondo’s group) (in Japanese). Gan to Kagaku Ryoho 17:2397–2403
Fujimoto S, Furue H, Kimura T et al (1991) Clinical outcome of postoperative adjuvant immunochemotherapy with sizofiran for patients with resectable gastric cancer: a randomised controlled study. Eur J Cancer 27:1114–1118
Maehara Y, Sugimachi K, Akagi M, Kakegawa T, Shimazu H, Tomita M (1992) Early postoperative chemotherapy following noncurative resection for patients with advanced gastric cancer. Br J Cancer 65:413–416
Imaizumi M, Kondo T, Kamei H (1994) Cooperative study of postoperative long-term adjuvant immunochemotherapy for prevention of postoperative recurrence of gastric cancer (second trial) (in Japanese). Gan No Rinsho 40:1243–1250
Tanaka N, Aichi A, Nagata H et al (1995) Preoperative intra tumor biological response modifier injection therapy for patients with stomach neoplasm (in Japanese). Nihon Rinsho Meneki Gakkai Kaishi 18:626
Osawa S, Shiroto H, Kondo Y, et al (1996) Randomized controlled study on adjuvant immunochemotherapy with carmofur (HCFU) for noncuratively resected and unresected gastric cancer (in Japanese). Gan To Kagaku Ryoho 23:327–331
Imaizumi M, Kondo T, Kamei H, Ichihashi H (1984) Cooperative studies on surgical adjuvant immunochemotherapy for prevention of postoperative recurrence of gastric cancer (in Japanese). Gan to Kagaku Ryoho 11:60–68
Nakajima T, Inokuchi K, Hattori T, et al (1985) A multi-institutional study on postoperative adjuvant immunochemotherapy of gastric cancer (in Japanese). Gan To Kagaku Ryoho 12:1850–1863
Tamada R, Inokuchi K, Hattori T et al (1987) A multi-institutional study on postoperative adjuvant immunochemotherapy of gastric cancer (II) (in Japanese). Gan to Kagaku Ryoho 14:716–722
Niimoto M, Hattori T, Tamada R, Sugimachi K, Inokuchi K, Ogawa N (1987) Postoperative adjuvant immunochemotherapy with mitomycin C, futraful and PSK for curatively resected cases of gastric cancer. In: Salmon SE (ed) Adjuvant therapy of cancer V. Grune & Stratton, Orlando, pp 515–524
Ichihashi H, Kondo T, Nakazato H (1987) Clinical results of a randomized controlled trial on the effect of adjuvant immunochemotherapy using Esquinon and Krestin in patients with curatively resected gastric cancer—7-year survival—Cooperative Study Group for Cancer Immunochemotherapy, Tokai Gastrointestinal Oncology Group (in Japanese). Gan to Kagaku Ryoho 14:2758–2766
Nakazato H, Koike A, Ichihashi H, Saji S, Danno M, Ogawa N (1989) An effect of adjuvant immunochemotherapy using krestin and 5-FU on gastric cancer patients with radical surgery (first report)—a randomized controlled trial by the cooperative study group. Study Group of Immuno-chemotherapy with PSK for Gastric Cancer (in Japanese). Gan to Kagaku Ryoho 16:2563–2576
Nakazato H, Koike A, Ichihashi H (1989) Results of a randomized controlled trial using adjuvant immunochemotherapy in patients surgically treated for gastric cancer (in Japanese). Biotherapy 3:1356–1360
Sakaguchi Y, Moriguchi S, Maehara Y et al (1989) Effect of postoperative long-term cancer chemotherapy (PLCC) on 15 year survival rate of gastric cancer patients (in Japanese). Biotherapy 3:1353–1355
Hattori T, Nakajima T, Nakazato H et al (1990) Postoperative adjuvant immunochemotherapy with mitomycin C, tegafur, PSK and/or OK-432 for gastric cancer, with special reference to the change in stimulation index after gastrectomy. Jpn J Surg 20:127–136
Kondo M (1994) Immunotherapy as adjuvant treatment after curative resection of gastric cancer [comment]. Lancet 344:274
Mitomi T, Ogoshi K (1986) Clinical study of PSK as an adjuvant immunochemotherapeutic agent against gastric cancer (in Japanese). Gan To Kagaku Ryoho 13:2532–2537
Saji S, Takao H, Kida H et al (1987) Effects of postoperative adjuvant immunochemotherapy using PSK for patients of gastric cancer, and its preventive effects on the recurrence (in Japanese). Prog Med 7:1703–1709
Maehara Y, Moriguchi S, Sakaguchi Y et al (1990) Adjuvant chemotherapy enhances long-term survival of patients with advanced gastric cancer following curative resection. J Surg Oncol 45:169–172
Maehara Y, Emi Y, Sakaguchi Y et al (1990) Postoperative long-term cancer chemotherapy (PLCC) is effective for patients with gastric cancer following curative resection (in Japanese). Nippon Geka Gakkai Zasshi 9:1368–1370
Maehara Y, Inutsuka S, Takeuchi H, Baba H, Kusumoto H, Sugimachi K (1993) Postoperative PSK and OK-432 immunochemotherapy for patients with gastric cancer. Cancer Chemother Pharmacol 33:171–175
Nakao I, Yokoyama T, Urushizaki I et al (1985) Clinical outcome of PSK for advanced gastric cancer (in Japanese). Oncologia 14:163–169
Nakazato H, Ichihashi H, Kondo T (1986) Clinical results of a randomized controlled trial on the effect of adjuvant immunochemotherapy using Esquinon and Krestin in patients with curatively resected gastric cancer. Cooperative Study Group of Cancer Immunochemotherapy, Tokai Gastrointestinal Oncology Group (in Japanese). Gan To Kagaku Ryoho 13:308–318
Nakajima T, Inokuchi K, Hattori T et al (1989) Multi-institutional cooperative study of adjuvant immunochemotherapy in gastric cancer—five-year survival rate (in Japanese). Gan to Kagaku Ryoho 16:799–806
Nio Y, Tsubono M, Tseng CC et al (1992) Immunomodulation by orally administered protein-bound polysaccharide PSK in patients with gastrointestinal cancer. Immunomodulation by orally administered protein-bound polysaccharide PSK in patients with gastrointestinal cancer (in Japanese). Biotherapy 4:117–128
Takahashi Y, Mai M, Nakazato H (2005) Preoperative CEA and PPD values as prognostic factors for immunochemotherapy using PSK and 5-FU. Anticancer Res 25:1377–1384
Saji S, Kida T, Kunieda K et al (1985) Five-year survival of gastric cancer patients treated with postoperative long term adjuvant immunochemotherapy. Prog Med 5:485–492
Akimoto M, Nishihira T, Kasai M (1986) Modulation of the anti-tumor effect of BRM under various nutritional or endocrine conditions (in Japanese). Gan to Kagaku Ryoho 13:1270–1276
Sugimachi K, Maehara Y, Ogawa M, Kakegawa T, Tomita M (1997) Dose intensity of uracil and tegafur in postoperative chemotherapy for patients with poorly differentiated gastric cancer. Cancer Chemother Pharmacol 40:233–238
Hanazaki K, Sodeyama H, Yokoyama S et al (1998) Postoperative chemotherapy may improve prognosis in unresectable gastric cancer. J Clin Gastroenterol 26:269–273
Kuroda Y, Horikawa N, Tsuji M et al (1998) Usefulness of polysaccharide K (PSK) as postoperative adjuvant immunotherapy in patients with stage IV gastric cancer. Int J Clin Oncol 3:311–316
Ogoshi K, Miyaji M, Iwata K, Kondo Y, Tajima T, Mitomi T (1990) Effect of postoperative adjuvant immunochemotherapy on panperitonitis carcimatous stomach cancer (in Japanese). Biotherapy 4:676–679
Sakamoto J, Koike A, Saji S, Teramukai S, Ohashi Y, Nakazato H (1992) Preoperative serum immunosuppressive acidic protein (IAP) test for the prognosis of gastric cancer: a statistical study of the threshold level and evaluation of the effect of the biological response modifier PSK. Jpn J Surg 22:530–536
Toge T, Yamaguchi Y (2000) Protein-bound polysaccharide increases survival in resected gastric cancer cases stratified with a preoperative granulocyte and lymphocyte count. Oncol Rep 7:1157–1161
Sakamoto J, Teramukai S, Nakazato H et al (2002) Efficacy of adjuvant immunochemotherapy with OK-432 for patients with curatively resected gastric cancer: a meta-analysis of centrally randomized controlled clinical trials. J Immunother 25:405–412
Algarra I, Collado A, Garrido F (1999) Protein bound polysaccharide PSK abrogates more efficiently experimental metastases derived from H-2 negative than from H-2 positive fibrosarcoma tumor clones. J Exp Clin Cancer Res 16:373–380
Nio Y, Tsubono M, Tseng CC et al (1992) Immunomodulation by orally administered protein-bound polysaccharide PSK in patients with gastrointestinal cancer. Biotherapy 4:117–128
Pedrinaci S, Algarra I, Garrido F (1999) Protein-bound polysaccharide (PSK) induces cytotoxic activity in the NKL human natural killer cell line. Int J Clin Lab Res 29:135–140
Shibata M, Nezu T, Fujisaki S, Andou K, Tomita R, Fukuzawa M (2002) Clinical potential of biological response modifiers combined with chemotherapy for gastric cancer. Dig Surg 19:255–260
Ueda Y, Fujimura T, Kinami S et al (2006) A randomized phase III trial of postoperative adjuvant therapy with S-1 alone versus S-1 plus PSK for stage II/IIIA gastric cancer: Hokuriku-Kinki Immunochemo-Therapy Study Group-Gastric Cancer (HKIT-GC). Jpn J Clin Oncol [Epub ahead of print]
Acknowledgments
The sponsor of this study had no role in data collection, data analysis, data interpretation, or writing this report. There were no funding sources. The corresponding author had full access to all data in this report and assumes final responsibility for the decision to submit this publication.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Oba, K., Teramukai, S., Kobayashi, M. et al. Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resections of gastric cancer. Cancer Immunol Immunother 56, 905–911 (2007). https://doi.org/10.1007/s00262-006-0248-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00262-006-0248-1